To determine whether loss of BAX conferred resistance selectively to S63845, or more generally to all cytotoxic drugs that induce apoptosis, isogenic Bak KO, Bax KO and Bak/Bax double KO cell lines from three independent Eμ-Myc lymphomas were generated using CRISPR/Cas9 gene editing and treated with standard-of-care agents that are part of the R-CHOP regimen, namely doxorubicin and vincristine [31]. This evidence concerns the gene BAK1 and lymphoma.